Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

Blood

Volumn 111, Issue 12, 2008, Pages 5530-5536

  Khouri, Issa F ^a   McLaughlin, Peter ^a   Saliba, Rima M ^a   Hosing, Chitra ^a   Korbling, Martin ^a   Lee, Ming S ^a   Medeiros, L Jeffrey ^a   Fayad, Luis ^a   Samaniego, Felipe ^a   Alousi, Amin ^a   Anderlini, Paolo ^a   Couriel, Daniel ^a   De Lima, Marcos ^a   Giralt, Sergio ^a   Neelapu, Sattva S ^a   Ueno, Naoto T ^a   Samuels, Barry I ^a   Hagemeister, Fredrick ^a   Kwak, Larry W ^a   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; CYCLOPHOSPHAMIDE; FLUDARABINE; METHOTREXATE; PROTEIN BCL 2; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; MYELOABLATIVE AGENT; VIDARABINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE PAIN; CANCER REGRESSION; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIARRHEA; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION COMPLICATION; LIVER TOXICITY; MALE; MORTALITY; NONMYELOABLATIVE CONDITIONING; OUTCOMES RESEARCH; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THORAX PAIN; ALLOTRANSPLANTATION; B LYMPHOCYTE; CYTOLOGY; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROSPECTIVE STUDY; RECURRENT DISEASE; REMISSION; SURVIVAL RATE;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; PROSPECTIVE STUDIES; RECURRENCE; REMISSION INDUCTION; SURVIVAL RATE; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 45149097052     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-136242     Document Type: Article

References (33)

1. Marks DI, Lush R. Cavenagh J. et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 2002:100:3108-3114.
2. Mandigers CMPW, Verdonck LF, Meijerink JPP et al. Graft-versus- lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant. 2003;32:1159-1163.
3. Peniket AJ, Ruizde Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003;31:667-678.
4. Khouri IF. Saliba RM. Giralt S, et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood. 2001;98:3595-3599.
5. Shipp MA, Harrington DP, Anderson JR, et al. The International Non- Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
6. Cheson BD, Horning SJ, Goiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma: NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244-1253.
7. Jazirehi AR, Bonavida D. Cellular and molecular signal transduction pathways modulated by ritux imab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: Implication in chemosensitization and therapeutic intervention. Oncogene. 2005;24:2121-2143.
8. Di Gaetano N. Xiao Y, Erba E. et al. Synegism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to cytotoxic activity of either drug alone. Br J Haematol. 2001;114:800-809.
9. Khouri IF, Lee MS, Saliba RM, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: affect of rituximab on immunomodulation and survival. Exp Hematol. 2004;32:28-35.
10. Schultz KR, Paquet J, Bader S, HayGlass KT. Requirements for B cells in T cell priming to minor histocompatibility antigens and development of graft- versus-host disease. Bone Marrow Transplant. 1995;16:289-295.
11. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-828.
12. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft- versus-host diseased 1. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11:945-955.
13. Lee WI, Cabanillas F, and Lee MS. Quantitative assessment of disease involvement by follicular lymphoma using real-time polymerase chain reaction measurement of t(14;18)-carrying cells. Int J Hematol. 2004;79:152-166.
14. Sanchez-Vega B, Vega F, Medeiros LJ, Lee MS, and Luthra R. Quantification of bcl-2/JH fusion
15. sequences and a control gene by multiplex realtime PGR coupled with automated amplicon sizing by capillary electrophoresis. J Mol Diagn. 2002;4:223-229.
16. Kaplan EL Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
17. Kalbfleish JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley; 1980.
18. van Besien K, Sobocinski K, Rowlings PA, et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood. 1998;92:1832-1836.
19. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9:995-1001.
20. Meeker T. Lowder J, Maloney D. et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood. 1985;65:1349-1363.
21. Press O, Appelbaum F, Ledbetter J, et al. Monoclonal antibody IF5 (anti- CD20) serotherapy of human B-cell lymphomas. Blood. 1987;69:584-591.
22. Hsu FJ, Komarovskaya M. CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti- CD20 antibody-coated lymphoma cells. J Immunother. 2002;25:455-468.
23. van Oers MHJ, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkirrs lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized Phase III intergroup trial. Blood. 2006:108:3295-3301.
24. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitox-antrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas-results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003-4008.
25. Kolb J, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462-2465.
26. Peggs KS, Thomson K, Hart DR et al. Doseescalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 2004;103:1548-1556.
27. Kusumi E, Kami M, KandaY, et al. Reduced-intensity hematopoietic stem-cell transplantation for malignant lymphoma: a retrospective survey of 112 adult patients in Japan. Bone Marrow Transplant. 2005;36:205-213.
28. Vigouroux S, Michallet M, Porcher R, et al. Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Haematologica. 2007;92:627-634.
29. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an
30. analysis from the Lymphoma Working Party of the European Group for Bood and Marrow Transplantation. Blood. 2002;100:4310-4316.
31. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab- containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin's lymphoma. Blood. 2004;104:3865-3871.
32. Rodriguez R, Nademanee A, Ruel N, et al. Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2006;12:1326-1334.
33. Rohatiner AZ, Nadler L. Davies AJ, et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol. 2007;25:2554-2559.